Kala Pharmaceuticals (NASDAQ:KALA)‘s stock had its “buy” rating restated by Wedbush in a research report issued on Thursday. They presently have a $46.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 152.75% from the company’s current price.

A number of other research firms also recently commented on KALA. J P Morgan Chase & Co set a $35.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Zacks Investment Research downgraded Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Oppenheimer initiated coverage on Kala Pharmaceuticals in a report on Tuesday, August 15th. They issued an “outperform” rating and a $46.00 target price for the company. Wells Fargo & Company initiated coverage on Kala Pharmaceuticals in a report on Monday, August 14th. They issued an “outperform” rating and a $24.00 target price for the company. Finally, Bank of America initiated coverage on Kala Pharmaceuticals in a report on Monday, August 14th. They issued a “buy” rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Kala Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.80.

Shares of Kala Pharmaceuticals (NASDAQ:KALA) traded up $0.18 during midday trading on Thursday, hitting $18.20. The company had a trading volume of 197,400 shares, compared to its average volume of 190,221. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00. Kala Pharmaceuticals has a 52-week low of $13.51 and a 52-week high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14). sell-side analysts predict that Kala Pharmaceuticals will post -2.08 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC acquired a new stake in Kala Pharmaceuticals in the third quarter valued at $54,251,000. Caxton Corp acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $12,430,000. Victory Capital Management Inc. acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $12,414,000. OxFORD Asset Management LLP acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $4,374,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Kala Pharmaceuticals during the 3rd quarter worth $4,037,000. 62.96% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/30/wedbush-reiterates-outperform-rating-for-kala-pharmaceuticals-kala.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.